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Abstract
Background and Objective Azilsartan medoxomil (AZL-
M) is an angiotensin II receptor blocker approved to treat
hypertension. After oral dosing,AZL-M is quickly hydrolyzed
to azilsartan (AZL). The aims of this study were to assess the
effects of age, sex, and race on the pharmacokinetics of AZL-
M in healthy subjects, as well as safety and tolerability.
Methods Sixty-one healthy adults were enrolled in this
phase I, single-blind, randomized placebo-controlled study
(placebo control was for assessment of safety/tolerability
only). Subjects were stratified by age (18–45 vs.
65–85 years), sex, and race (black vs. white) and given oral
AZL-M 60 mg (3 9 20 mg capsules) or placebo as a sin-
gle dose (Day 1) and consecutive daily doses (Days 4–8)
(6:2 ratio for AZL-M:placebo per group). Pharmacokinet-
ics were evaluated (AZL-M patients only) on Days 1–3 and
8–9 and safety/tolerability was monitored.
Results Age, sex, and race had no clinically meaningful
effect on AZL exposures after single or multiple dosing.
Pharmacokinetic parameters remained similar between
Days 1 and 8 for each age, sex, and race subgroup. The
frequency of adverse events was similar for AZL-M (32 %)
and placebo (29 %). No discontinuations or serious adverse
events occurred.
Conclusions Based on these pharmacokinetic and
safety/tolerability findings, no AZL-M dose adjustments
are required based on age, sex, or race (black/white).
Key Points
Age, sex, and race appear to have no clinically
significant impact on the pharmacokinetics of
azilsartan.
No adjustments in azilsartan medoxomil dosage are
required on the basis of age, sex, or race.
1 Introduction
The use of drugs acting on the renin-angiotensin system
(RAS), principally angiotensin converting enzyme inhibi-
tors and angiotensin II receptor blockers (ARBs), has
become established as an important component in the
contemporary management of patients with hypertension
[1]. The latest JNC8 Guidelines recommend RAS inhibi-
tors (alone or in combination with other drugs) as the first-
line therapy treatment for patients with chronic kidney
disease (CKD), with or without diabetes mellitus and for all
ages and races [1]. These agents are also one of the rec-
ommended first-line agents for those without CKD, espe-
cially in non-black patients [1]. As second-line agents,
RAS inhibitors are one of the recommended components of
combination therapy available to patients irrespective of
age, sex, or race [1].
Azilsartan medoxomil (AZL-M) is a potent ARB
approved for the treatment of hypertension at a dose of
20–80 mg once daily, alone or in combination with other
antihypertensive agents [2–5]. After oral dosing, AZL-M (a
pro-drug) is rapidly hydrolyzed during absorption in the gut
and/or gut wall to form its active moiety, azilsartan (AZL)
[2, 5]. Unchanged AZL-M is not detected in blood at any
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time. Based on previous pharmacokinetic analyses, peak
plasma concentrations of AZL are reached within 1.5–3 h
after oral dosing, elimination half-life is approximately
11 h, and renal clearance is approximately 2.3 mL/min [2,
5]. Assuming total conversion to AZL, the apparent oral
clearance of AZL-M after non-compartmental analysis is
approximately 1.5 L/h [6]. Systemic exposure of AZL with
the capsule formulation of AZL-M (as used in the initial
clinical development phase and in the current study) was
shown to be higher when the capsules were administered
with food. This food-effect response was minimized with
the commercial tablet formulation.
Both renal and hepatic metabolism contribute to the
elimination of AZL, although neither mild-to-severe renal
impairment nor mild-to-moderate hepatic impairment has
any clinically relevant impact on AZL exposure [2, 5, 7, 8].
Systemic exposure of the main metabolite of AZL (M-II;
formed by O-dealkylation via the cytochrome P450 2C9
isoform) is also unchanged with hepatic impairment, but is
increased in patients with renal impairment; however, this
increase has no clinical relevance because M-II is not
pharmacologically active [2, 5, 7, 8]. Similarly, the minor
metabolite M-I (formed by decarboxylation) is not phar-
macologically relevant [2, 5].
The possibility of alterations in AZL pharmacokinetics
in the elderly is a particularly important consideration
because of the potential for age-related impairments in
physiologic processes and the resultant decline in drug
metabolism and excretion [9, 10]. In addition, potential
pharmacokinetic differences according to sex and/or race
remain a key consideration with all pharmacologic agents.
If clinically relevant differences in drug exposure are pre-
sent, dose adjustments or altered dosing schedules may be
required in specific patient populations to maximize effi-
cacy or minimize the risk of adverse effects.
Because hypertension can affect any individual,
regardless of age, sex, or race, it is important to establish
the pharmacokinetic and tolerability/safety profile of AZL
within these populations. The current study evaluated the
possible effects of age, sex, and race on AZL pharma-
cokinetics and AZL safety/tolerability after single and
multiple (five consecutive) daily doses of AZL-M 60 mg in
healthy adult subjects.
2 Methods
This was a phase I, single-center, single-blind, random-
ized, parallel-group, single- and multiple-dose, placebo-
controlled study. The placebo-controlled component was
for the assessment of safety only. The study was per-
formed at Arkansas Research Medical Testing, Little
Rock, AR, USA, where it was approved by the
Institutional Review Board for Arkansas Research Med-
ical Testing, Little Rock, AR, USA and undertaken in
accordance with the Declaration of Helsinki. Written
informed consent was obtained directly from all partici-
pants prior to entry into the study and prior to any study
procedures.
2.1 Study Participants
The study population consisted of 61 healthy, non-hyper-
tensive black or white men or women aged 18–45 years
(‘‘young’’) or 65–85 years (‘‘elderly’’), with a body mass
index (BMI) of 18–33 kg/m2 and minimum body weight of
50 kg. Exclusion criteria included: (1) history of drug/al-
cohol abuse; (2) history or clinical manifestations of sig-
nificant metabolic, hematologic, pulmonary, cardiovascular,
gastrointestinal, neurologic, hepatic, renal, urologic,
immunologic, or psychiatric disorders (unless approved on a
case-by-case basis); (3) abdominal surgery or thoracic or
nonperipheral vascular surgery in the previous 6 months; (4)
systolic blood pressure[140 or\110 mmHg, or a diastolic
blood pressure[90 or\70 mmHg; (5) history or presence
of an abnormal, clinically significant 12-lead ECG result; (6)
pregnancy/lactation; (7) hemoglobin\12 g/dL; (8) alanine
transaminase level [1.5 9 upper limit of normal, active
liver disease, or jaundice; (9) blood donation or acute blood
loss [500 mL in the previous 30 days; (10) history of
cancer (except basal cell or stage 1 squamous cell carcinoma
of the skin) that had not been in remission for the previous
5 years; and (11) tobacco or nicotine product use in the
previous 30 days.
The following medications/food products were prohib-
ited for the duration of the subject’s participation in the
study and for varying time periods prior to study entry: (1)
prescription medications (except those approved on a case-
by-case basis) and neutraceuticals (28 days prior to study
entry); (2) over-the-counter medications (except those
approved on a case-by-case basis) and vitamin supplements
(14 days prior to study entry); and (3) alcohol- and caf-
feine-containing products, foods, or beverages containing
Seville (sour) orange- and grapefruit-containing products
(72 h prior to study entry).
Subjects were stratified according to age (young [Y]or
elderly [E]), sex (male [M] or female [F]), and race (black
[B] or white [W]) into eight treatment groups (YFB, EFB,
YMB, EMB, YFW, EFW, YMW, EMW). Each group
consisted of eight subjects—six randomized to receive
AZL-M 60 mg and two randomized to receive placebo.
Because of the difficulty in enrollments, the EFB group
was an exception (n = 5), with no subjects receiving pla-
cebo. Following screening (Days -28 to -2), subjects
were admitted to the clinic on Day -1 and confined to the
clinic for a total of 9 nights until Day 9.
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2.2 Treatment Allocation
Randomly allocated study treatment (AZL-M 60 mg
[3 9 20 mg oral capsules] or matching placebo) was
administered once per day in the morning as a single dose
on Day 1 and consecutive single doses on Days 4–8,
inclusive. Treatment was administered immediately fol-
lowing consumption of a standardized breakfast containing
approximately 600–800 kcal and approximately 30 % fat.
The 60-mg dose of the AZL-M capsule was chosen for the
current study as it provided a significant decrease in blood
pressure, while being safe and well tolerated, in early
clinical studies where AZL-M was administered without
regard to meals (US FDA, 2011).
2.3 Bioanalytical Methods
Blood samples were obtained at time points up to 72 h
post-dose after the single dose on Day 1, before dosing on
Days 6, 7, and 8, and up to 24 h post-dose after the last
dose on Day 8 to determine the concentrations of AZL. All
blood samples were collected into chilled 6-mL tubes
containing potassium ethylene diamine tetra-acetic acid
and centrifuged, and the plasma was then removed. Sam-
ples were stored at approximately -70 C or lower.
The AZL concentrations in plasma samples were
determined using a validated liquid chromatography-tan-
dem mass spectrometry assay at Covance Laboratories,
Madison, WI, USA. The samples were acidified and the
internal standard was added. AZL and the internal standard
were then extracted using OASIS HLB, 96-well solid-
phase extraction plates (Waters, Milford, MA, USA).
Liquid chromatography separation was obtained using an
Xterra RP18 column (Waters; 250 9 2.1 mm, 5 lm).
The mobile phase consisted of an acetonitrile:water:acetic
acid gradient (60:40:0.05, v:v:v)/acetonitrile and was
pumped through the column at a flow rate of 0.2 mL/min.
For detection, an API 3000 mass spectrometer (AB Sciex,
Framingham, MA, USA) with positive ion electrospray in
multiple-reaction monitoring mode was used. The LC-MS/
MS assay range and precision for the quality control
samples in this study were 1.00–2500 ng/mL and
3.6–8.0 %, respectively.
2.4 Pharmacokinetic and Safety Assessments
Pharmacokinetic variables derived from AZL concentra-
tions in plasma were calculated, including AUC0–? (area
under the plasma concentration-time curve from time 0 h
to infinity, single dose only, Day 1); AUC0–24 (area under
the plasma concentration-time curve from time 0 to 24 h
post dose [one dose interval], after multiple doses only,
Day 8); Cmax (maximum observed drug concentration in
plasma); tmax (time to reach Cmax); and t (terminal half-
life, single dose only). Pre-dose trough concentration
(Cmin) was also assessed on Days 6–8. Pharmacokinetic
parameters were derived using noncompartmental methods
with WinNonlin Professional Version 4.10 (Pharsight
Corp., Mountain View, CA, USA).
Placebo subjects were assessed for safety/tolerability
only. Safety and tolerability parameters included adverse
events, clinical laboratory tests (hematology and serum
chemistry), vital signs, 12-lead electrocardiogram, and
physical examination findings.
2.5 Statistical Analysis
All data analyses were performed using Statistical Analysis
System (SAS, Version 9.1, SAS Institute, Cary, NC,
USA). An alpha of 0.05 was used for any hypothesis tests
performed. Descriptive statistics were used to summarize
the pharmacokinetic parameters according to age, sex, and
race. An analysis of covariance (ANCOVA) was performed
(with fixed effects for age, sex, and race, and body weight
as a covariate) on the natural logarithms of the pharma-
cokinetic variables AUC0–?, AUC0–24, and Cmax. Point
estimates for comparing groups (elderly vs. young, female
vs. male, white vs. black) were calculated and presented as
ratios; these were obtained by exponentiating estimates of
the difference in between-group least-squares means on the
log-transformed parameters obtained within the framework
of the ANCOVA model. Confidence intervals (CIs) for
these estimates were similarly obtained by exponentiating
the endpoints of 90 % CIs for the between-group differ-
ences of the log-transformed parameters.
To assess linear kinetics of AZL, an analysis of variance
(ANOVA) with fixed effects for age, race, sex, day,
interaction terms age-by-race, age-by-sex, race-by-sex, and
age-by-race-by-sex, and subject nested within age-by-race-
by-sex as random effect was performed on the natural
logarithms of AUC0–? for the single dose (Day 1) and
AUC0–24 for the multiple dose (Day 8) for AZL. A 90 % CI
for the ratio of the least squares means of the multiple-dose
AUC0–24 relative to the single-dose AUC0–? was derived
within the framework of ANOVA.
The natural logarithms of pre-dose concentrations on
Days 6, 7, and 8 were analyzed to assess the achievement
of steady state. An ANOVA with the same interaction
terms listed above was performed. Within the model, a
pairwise t test was used to assess the achievement of steady
state by comparing the pre-dose concentration between
study days.
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3 Results
3.1 Subject Characteristics
Demographic and baseline characteristics for the subject
population are summarized in Table 1. Mean age was
approximately 31 years for ‘‘young’’ subjects and70 years for
‘‘elderly’’ subjects, and mean BMI was approximately 27 kg/
m2. TheAZL-Mand placebo groups had similar demographic
characteristics. All subjects completed the study.
3.2 Azilsartan Pharmacokinetics
The AZL concentration-time profiles after a single dose
(Day 1) and after multiple dosing (Day 8) of AZL-M
according to age, sex, and race are shown in Figs. 1 and 2,
and pharmacokinetic parameter estimates are shown in
Table 2. Elderly subjects had a higher total AZL exposure
(AUC) after both a single dose (ratio 1.36, 90 % CI 1.05,
1.77) and after multiple dosing (ratio 1.26, 90 % CI 1.01,
1.57) compared with young subjects (Table 3; Fig. 2).
Elderly subjects also had higher peak AZL exposure (Cmax)
after both a single dose (ratio 1.37, 90 % CI 1.02, 1.86) and
after multiple dosing (ratio 1.15, 90 % CI 0.89, 1.49)
compared with young subjects (Table 3; Fig. 3). There
were no clinically relevant differences for female vs. male
subjects or black vs. white subjects in terms of total or peak
AZL exposure after either a single dose or after multiple
dosing (Table 3; Figs. 2, 3). No notable differences in time
to peak exposure (tmax) were evident according to age, sex,
and race (Table 2).
An assessment of pooled data from all subjects who
received AZL-M showed no difference in AZL exposure
between a single dose AUC0–? (Day 1) and AUC0–24 at
steady state after multiple dosing (Day 8) (LS mean 22281
vs. 22141 ngh/mL, respectively; AUC0–? Day 1/AUC0–24
Day 8 ratio 0.99, 90 % CI 0.93, 1.06). Similarly, no
notable differences between single-dose (Day 1) and mul-
tiple-dose (Day 8) pharmacokinetic parameters were evi-
dent according to age, sex, or race (Tables 2, 3).
Steady state plasma trough AZL concentrations (Cmin)
on Days 6 through 8 differed less than 20 % (213.2, 249.5,
and 250.6 ng/mL for Days 6, 7, and 8, respectively). No
statistically significant difference was noted between Cmin
values on Days 7 and 8 (p = 0.947).
The results of subgroup analyses suggested a higher
AZL Cmax and AUC (56–57 % higher on Day 8) in elderly
women compared with young women, although this was
based on relatively small numbers of subjects (11 vs. 12,
respectively) and one young black woman had substan-
tially lower Cmax and AUC values (322 ng/mL and
3059 ngh/mL on Day 8) compared with the rest of the
study population. Elderly women also had higher AZL
Cmax (57 % higher) and AUC0–24 (35 % higher) compared
Table 1 Demographic and baseline characteristics stratified by age, sex, and race
Demographic variable Azilsartan medoxomil Placebo Azilsartan medoxomil Placebo
Age Elderly Young
N 23 6 24 8
Age, years (mean ± SD) 68.7 (4.8) 73.0 (5.8) 31.4 (8.6) 30.0 (7.0)
Sex, female/male (n) 11/12 2/4 12/12 4/4
Race, white/black (n) 12/11 4/2 12/12 4/4
BMI, kg/m2 (mean ± SD) 28.2 (3.3) 26.7 (3.5) 25.8 (3.8) 27.0 (4.2)
Body weight, kg (mean ± SD) 81.2 (12.6) 81.0 (18.9) 75.9 (10.4) 81.4 (15.5)
Sex Female Male
N 23 6 24 8
Age, years (mean ± SD) 49.0 (19.7) 47.2 (21.5) 50.2 (20.9) 49.4 (25.4)
Race, white/black (n) 12/11 4/2 12/12 4/4
BMI, kg/m2 (mean ± SD) 27.7 (4.1) 26.4 (4.5) 26.4 (3.3) 27.3 (3.4)
Body weight, kg (mean ± SD) 74.5 (9.8) 71.5 (12.0) 82.4 (12.2) 88.6 (15.8)
Race White Black
N 24 8 23 6
Age, years (mean ± SD) 49.1 (23.0) 54.5 (24.0) 50.2 (17.1) 40.3 (20.7)
Sex, female/male (n) 12/12 4/4 11/12 2/4
BMI, kg/m2 (mean ± SD) 27.2 (3.5) 27.5 (2.2) 26.8 (4.0) 26.1 (5.4)
Body weight, kg (mean ± SD) 78.8 (12.9) 83.7 (11.8) 78.2 (10.5) 77.9 (21.9)
BMI body mass index, Black Black or African American, Elderly age 65–85 years, Young age 18–45 years, SD standard deviation
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with elderly men, although individual Cmax and AUC
values for both elderly women and men overlapped.
3.3 Safety and Tolerability
The incidence and pattern of adverse events in subjects
receiving AZL-M did not appear to be influenced by age,
sex, or race (Table 4). The percentage of subjects reporting
at least one adverse event was similar for AZL-M (32 %;
15/47 subjects) and placebo (29 %; 4/14 subjects). No
subjects discontinued the study and no serious adverse
events were reported. Headache was the most common
adverse event (reported by four subjects [8.5 %] receiving
AZL-M). Nausea, fatigue, blood pressure increase,
Fig. 1 Azilsartan
concentration–time profiles
after a single dose (Day 1) of
azilsartan medoxomil according
to age (top), sex (middle), and
race (bottom). All data are
mean ± standard error of the
mean
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dizziness, and hot flush were each experienced by two
subjects (4.3 %) receiving AZL-M. Treatment-emergent
adverse events that were each reported by one subject were
flatulence, vomiting, injection site hemorrhage, contusion,
heart rate increase, decreased appetite, muscle spasms, and
muscle tightness. Two subjects had abnormal laboratory
values during the study (one AZL-M subject with abnormal
alanine transaminase, aspartate aminotransferase, and c-
glutamyltransferase and one placebo subject with an
abnormal creatine kinase value). No subject discontinued
the study because of an abnormal laboratory value, and no
abnormal laboratory value was considered a serious
Fig. 2 Azilsartan
concentration–time profiles
after multiple dosing (Day 8) of
azilsartan medoxomil according
to age (top), sex (middle), and
race (bottom). All data are
mean ± standard error of the
mean
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adverse advent. There were no clinically important changes
in 12-lead ECGs or physical examination findings.
Mean blood pressure tended to decrease over the study
period in subjects receiving AZL-M. Transient systolic
blood pressure measurements meeting the predefined cri-
teria of very low (\90 mmHg) were recorded for seven
subjects (15 %) on AZL-M, but hypotension was not
reported as an adverse event in any subject. An overall
decrease in blood pressure was expected and is consistent
with the clinical benefit of the drug. Of particular relevance
to the aims of the current study, there was no evidence of a
relationship of age, sex, or race with very low blood
pressure measurements.
4 Discussion
In this single-center, single-blind, randomized, parallel-
group, single- and multiple-dose study, we investigated
the impact of age, sex, and race on exposure to AZL (the
active moiety of AZL-M) after administration of AZL-M
60 mg (capsule formulation) once daily. Although AZL-
M has been shown to decrease blood pressure in a dose-
dependent manner in a general population of subjects
with mild-to-moderate hypertension [11–13], pharma-
cokinetic analyses such as the current study are important
for determining the potential need for dosing adjustments
in key subpopulations. We found that sex and race did
Table 2 Descriptive statistics
for azilsartan plasma
pharmacokinetic parameters
according to age, sex, and race
Parameter Arithmetic mean ± SD or median [min, max]
Age Elderly (n = 23) Young (n = 24)
Single dose (Day 1)
AUC0–? (ngh/mL) 26739 ± 9027a 21424 ± 7221b
Cmax (ng/mL) 3031 ± 1110 2520 ± 1206
tmax (h) 6.0 [3.0, 12.0] 5.0 [3.0, 24.0]
t (h) 12.17 ± 1.94
a 10.64 ± 1.47b
Multiple dose (Day 8)
AUC0–24h (ngh/mL) 25445 ± 9563 21502 ± 7693
Cmax (ng/mL) 3253 ± 1435 3049 ± 1319
tmax (h) 4.0 [1.0, 8.0] 4.0 [2.0, 8.0]
Sex Female (n = 23) Male (n = 24)
Single dose (Day 1)
AUC0–? (ngh/mL) 25773 ± 9525a 22348 ± 7195b
Cmax (ng/mL) 3023 ± 1382 2527 ± 901
tmax (h) 6.0 [3.0,12.0] 4.0 [3.0, 24.0]
t (h) 11.40 ± 1.37
a 11.38 ± 2.27b
Multiple dose (Day 8)
AUC0–24h (ngh/mL) 25328 ± 9313 21614 ± 8037
Cmax (ng/mL) 3536 ± 1482 2778 ± 1156
tmax (h) 4.0 [1.0, 8.0] 4.0 [2.0, 8.0]
Race White (n = 24) Black (n = 23)
Single dose (Day 1)
AUC0–? (ngh/mL) 25930 ± 8827b 22028 ± 7840a
Cmax (ng/mL) 2816 ± 1228 2721 ± 1146
tmax (h) 6.0 [3.0, 24.0] 6.0 [3.0, 12.0]
t (h) 11.67 ± 2.09
b 11.09 ± 1.58a
Multiple dose (Day 8)
AUC0–24h (ngh/mL) 24320 ± 8752 22505 ± 8932
Cmax (ng/mL) 3365 ± 1053 2924 ± 1624
tmax (h) 4.0 [2.0, 8.0] 4.0 [1.0, 8.0]
t terminal half-life, AUC0–24h area under the plasma concentration-time curve from time 0 to 24 h post
dose, AUC0–? area under the plasma concentration-time curve from time 0 h to infinity, Cmax maximum
observed drug concentration in plasma, tmax time to reach Cmax, SD standard deviation, min minimum, max
maximum
a n = 22
b n = 23
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not have any clinically relevant influence on AZL
exposure. Although a small increase in AZL exposure
was seen in elderly vs. young subjects, the differences
(36 % higher AUC0–? [single dose], 26 % higher
AUC0–24 [multiple dose], and 37 % higher single-dose
Cmax) were not considered to be clinically relevant.
Further subgroup analyses suggested higher AZL expo-
sure in elderly women compared with young women, but
the analysis was relatively underpowered and skewed by
an outlier. Similarly, elderly women also had higher AZL
exposure compared with elderly men, although there was
overlap in individual values, suggesting no need for dose
adjustments. These findings in subpopulations supplement
other recently published pharmacokinetic data suggesting
that there is also no clinically relevant effect of any
degree of renal impairment (including end-stage renal
disease) on AZL exposure after AZL-M administration
[7]. The pharmacokinetic parameter estimates in the
current analysis are broadly consistent with those reported
in previous studies [2, 5, 7]. Mean elimination half-life
was 10–12 h across the different subgroups and median
tmax was 4.0 h after multiple dosing. We also confirmed
that oral AZL-M administration displayed linear kinetics
(ratio close to unity) and that the Day 8 multiple-dose
measurements were carried out at steady state in the
absence of any continuous AZL accumulation (no sta-
tistically significant difference between Cmin values on
Days 7 and 8) or any unexpected accumulation or
reduction in exposure that might reflect time-dependent
changes in AZL pharmacokinetics.
The ARBs are a recommended treatment option in
elderly hypertensive patients, especially in those with CKD
and proteinuria [1, 9, 10]. The current study provides
reassuring pharmacokinetic data for AZL-M in this vul-
nerable population. This class of drugs is also a recom-
mended treatment option in black hypertensive patients,
especially in those with diabetes and/or kidney disease and
especially in combination with either a diuretic or a cal-
cium channel blocker (although it has been suggested that
ARBs may be less effective in black patients when used as
monotherapy) [1, 14, 15]. Preliminary results based on an
analysis of three randomized controlled trials suggest that,
at maximum approved doses, AZL-M lowers blood pres-
sure more effectively in black patients with hypertension
Table 3 Statistical analysis of
azilsartan plasma
pharmacokinetic parameters
according to age, sex, and race
Parameter LS mean LS mean Ratio [90 % CI]
Age Elderly (n = 23) Young (n = 24) Elderly/young
Single dose (Day 1)
AUC0–? (ngh/mL) 26,003a 19,062b 1.36 [1.05, 1.77]
Cmax (ng/mL) 2876 2093 1.37 [1.02, 1.86]
Multiple dose (Day 8)
AUC0–24 (ngh/mL) 24,375 19,384 1.26 [1.01, 1.57]
Cmax (ng/mL) 3036 2638 1.15 [0.89, 1.49]
Sex Female (n = 23) Male (n = 24) Female/male
Single dose (Day 1)
AUC0–? (ngh/mL) 22,577a 21,955b 1.03 [0.78, 1.36]
Cmax (ng/mL) 2478 2430 1.02 [0.75, 1.39]
Multiple dose (Day 8)
AUC0–24 (ngh/mL) 22,565 20,938 1.08 [0.86, 1.36]
Cmax (ng/mL) 3049 2627 1.16 [0.89, 1.52]
Race White (n = 24) Black (n = 23) White/black
Single dose (Day 1)
AUC0–? (ngh/mL) 24,599b 20,150a 1.22 [0.95, 1.58]
Cmax (ng/mL) 2547 2364 1.08 [0.81, 1.44]
Multiple dose (Day 8)
AUC0–24 (ngh/mL) 22,974 20,565 1.12 [0.90, 1.39]
Cmax (ng/mL) 3201 2502 1.28 [0.99, 1.65]
CI confidence interval, AUC0–24h area under the plasma concentration-time curve from time 0 to 24 h post
dose, AUC0–? area under the plasma concentration-time curve from time 0 h to infinity, Cmax maximum
observed drug concentration in plasma
a n = 22
b n = 23
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than the ARBs olmesartan or valsartan [16]. The current
study complements this evidence by suggesting that AZL-
M can be used effectively in black patients without the
need for dose adjustment.
The current study also provided the opportunity to
assess the safety and tolerability of AZL-M in these sub-
populations. We found that AZL-M 60 mg (capsule for-
mulation) once daily was safe and well tolerated
irrespective of age, sex, and race. It should be noted that
the AZL-M capsule formulation used in the current study
was switched to a once-daily tablet formulation (20, 40, or
80 mg) during later-phase clinical development. Unlike the
capsule formulation, the commercially available tablet is
not affected by food and provides approximately 70 %
greater exposure to AZL compared with the capsule in the
fasted state [6].
5 Conclusion
In this study, age, sex, and race had no clinically relevant
influence on exposure to AZL (the active moiety of AZL-
M) during single and multiple dosing of AZL-M 60-mg
capsules once daily in healthy volunteers. Similarly, age,
sex, and race had no impact on AZL-M safety and toler-
ability. These results suggest that no AZL-M dose
adjustments are required based on age, sex, or race (black
or white).
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Fig. 3 Between-group ratios for AUC and Cmax after a single dose
(Day 1) and multiple dosing (Day 8). Data are ratios of the least
squares means with associated 90 % confidence intervals.
AUC = AUC0–? for single dosing (Day 1) and AUC0–24 for multiple
dosing (Day 8). The reference groups are young, male, and black.
Cmax maximum observed drug concentration in plasma, AUC area
under the plasma concentration-time curve, AUC0–? area under the
plasma concentration-time curve from time 0 h to infinity, AUC0–24
area under the plasma concentration-time curve from time 0 to 24 h
post dose
Table 4 Adverse events reported by C2 subjects in any group by
age, sex, and race
Preferred terma AZL-M Placebo AZL-M Placebo
All subjects N = 47 N = 14 – –
Any event 15 (31.9) 4 (28.6) – –
Headache 4 (8.5) 0 – –
Dizziness 2 (4.3) 0 – –
Nausea 2 (4.3) 2 (14.3) – –
Fatigue 2 (4.3) 0 – –
Hot flush 2 (4.3) 0 – –
BP increased 2 (4.3) 0 – –
Age Young Elderly
N = 24 N = 8 N = 23 N = 6
Headache 3 (12.5) 0 1 (4.3) 0
Dizziness 2 (8.3) 0 0 0
Nausea 2 (8.3) 2 (25.0) 0 0
Fatigue 2 (8.3) 0 0 0
Hot flush 2 (8.3) 0 0 0
BP increased 0 0 2 (8.7) 0
Sex Male Female
N = 24 N = 8 N = 23 N = 6
Headache 1 (4.2) 0 3 (13.0) 0
Dizziness 0 0 2 (8.7) 0
Nausea 1 (4.2) 2 (25.0) 1 (4.3) 0
Fatigue 2 (8.3) 0 0 0
Hot flush 2 (8.3) 0 0 0
BP increased 1 (4.2) 0 1 (4.3) 0
Race White Black
N = 24 N = 8 N = 23 N = 6
Headache 3 (12.5) 0 1 (4.3) 0
Dizziness 2 (8.3) 0 0 0
Nausea 2 (8.3) 1 (12.5) 0 1 (16.7)
Fatigue 2 (8.3) 0 0 0
Hot flush 2 (8.3) 0 0 0
BP increased 1 (4.2) 0 1 (4.3) 0
Data are presented as n (%)
AZL-M azilsartan medoxomil, BP blood pressure
a A subject who reported C2 adverse events within the same pre-
ferred term was counted only once for that term
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